Introduction: CEA is the most frequently used tumor marker in colorectal cancer. There may be an improvement in its efficacy when used in association with CA 242. Aim: The purpose of this study was to evaluate the efficacy of preoperative serum levels of the tumor markers CA 242 and CEA in the staging and postoperative follow-up of colorectal adenocarcinoma patients. Patients and methods: Of a series of 134 patients with colorectal adenocarcinomas 90 underwent radical surgery and 44 palliative surgery. The control group consisted of 22 organ donors. The cutoff serum levels utilized were 5 ng/mL for CEA and 20 U/mL for CA 242. The mortality during follow-up was recorded in order to determine the duration of survival. The data were submitted to statistical analysis using diagnostic tests, the chi-square test, survival analysis (Kaplan and Meier) and ROC curves. A significance level of p ≤ £ 0.05 was applied. ' stages A, B, C and D was 27.8%, 32.4%, 32.1% and 66.7%, respectively . The sensitivity of CA 242 was 11.1%, 16.2%, 30.8% and 50%. When both markers were combined, the sensitivity was 33.3%, 48.6%, 40.7% and 72.5%. In the group of patients who underwent radical surgery the mean survival was 60.47 months for those with high preoperative CEA levels, 52.22 months for those with high preoperative CA 242 levels, and 44.80 months for those with elevated levels of both markers. There was a statistically significant difference in survival between patients undergoing radical surgery with elevated CA 242 levels, especially when CEA was also elevated, and patients without elevated CA 242. Conclusion: Preoperative serum levels of CA 242 showed less efficacy than CEA levels for the staging of colorectal adenocarcinoma patients. Elevated preoperative serum levels of CA 242 alone were related to poor survival, especially in association with high levels of CEA. (Int J Biol Markers 2003; 18: 182-7)
INTRODUCTION
Colorectal carcinoma is one of the main causes of death from cancer in developed countries (1) (2) (3) (4) . Although there has been considerable progress in the diagnosis and treatment of cancer, there has been little improvement in the survival of patients with colorectal cancer (1, (3) (4) (5) . This is due to the low sensitivity of the noninvasive tests used for early detection of the disease (3, (6) (7) (8) . Such early detection would ideally be achieved by means of a simple serological test, through the use of tumor markers, or by means of molecular genetic studies to recognize which individuals have a predisposition for developing cancer (3, 4, 9, 10) .
Ongoing research into the best serum markers for digestive system tumors has made the following markers available for clinical use: CA 19-9, CA 50, CA 195, CA 72-4, CA 242, p53, TATI, TPA, TPS, TPM and VEGF. However, none of these appears to be superior to CEA for de-tecting colorectal cancer (8, (11) (12) (13) (14) (15) (16) (17) (18) .
The tumor marker CA 242 is defined by the C242 monoclonal antibody. This has been obtained through immunizing mice with a human colorectal adenocarcinoma cell strain (COLO 205), with definition via a high molecular weight glycoprotein (19, 20) . Carpelan-Holmström et al (21) studied 259 patients with colorectal carcinoma including determination of the markers CEA and CA 242. They observed a significantly longer survival in patients with normal CEA levels (≤5 ng/mL) than in patients who had high CEA levels (>5 ng/mL), and in patients with normal CA 242 levels (≤20 U/mL) than in those with high CA 242 levels (>20 U/mL). They also observed that the prognosis was worse when the preoperative CEA and CA 242 levels were both above normal.
The study of tumor markers continues to be a challenge. There is particular interest in CA 242, mainly because of the lack of research reports in the literature. Forslund et al (22) conducted a comparative study of postoperative survival using the preoperative serum concentrations of anti-p53 and CA 242 in colorectal cancer patients. They showed that serum CA 242 has no prognostic significance and that preoperative CEA can identify high-risk patients who could benefit from neoadjuvant therapy. A comparative analysis of serum CA 242 and CA 19-9 has been reported by Spila et al (23) , showing that CA 242 determination offers a particular advantage over CA 19-9, while CEA remains the marker of choice in monitoring colorectal cancer patients.
The purpose of this study was to evaluate the efficacy of preoperative serum levels of the tumor markers CA 242 and CEA in the staging and postoperative follow-up of colorectal adenocarcinoma patients.
PATIENTS AND METHODS
The study included 134 patients with colorectal adenocarcinomas who were examined, cared for and operated on in the Surgical Gastroenterology Department of Hospital São Paulo, Escola Paulista de Medicina (EPM), Federal University of São Paulo (UNIFESP), between December 1993 and March 1999. The research protocol had the approval of the Research Ethics Committee of Hospital São Paulo.
There were 58 male patients (43.3%) and 76 females (56.7%). Their ages ranged from 19 to 87 years, with an average of 61.7 years (SD=13.47). Ninety patients (67.2%) underwent surgery considered radical and 44 (32.8%) underwent palliative surgery. According to the Broders classification, 57 of the carcinomas were highly differentiated (grade I), 68 were moderately differentiated (grade II) and five were poorly differentiated (grade III); none of the carcinomas were undifferentiated (grade IV). In four patients it was impossible to define the histological differentiation. The patients were divided according to the Dukes classification (24) modified by Turnbull (25) into subgroups A, B, C and D including 18 patients (13.4%), 37 patients (27.6%), 28 patients (21%) and 51 patients (38%), respectively.
As control, blood samples from 22 organ donors were used. None of these individuals had cholelithiasis, obstruction of the bile ducts, cirrhosis, hepatic schistosomiasis or pancreatitis. The control group included 15 men (68.2%) and seven women (31.8%) ranging in age from 19 to 66 years, with an average of 35.9 years (SD=16.07).
The serum CEA assays were performed using dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). CEA values up to 5 ng/mL were considered normal. For serum CA 242 determination the CanAg CA 242 enzyme immunometric assay was used; CA 242 values up to 20 U/mL were considered normal.
When the results of the present study were analyzed, the preoperative serum levels of the tumor markers were related to presence of disease, staging and duration of survival. Diagnostic tests and the chi-square test were used for evaluating the relationship between specific stages and mortality. Survival was analyzed using the Kaplan-Meier curve. The log-rank test was applied for comparisons between two or more Kaplan-Meier curves. ROC curves were used for evaluating the association between tumor marker serum levels and modified Dukes staging (26) . In all tests, 0.05 or 5% (α ≤ 0.05) was set as the significance level for rejection of the null hypothesis.
RESULTS
High CEA levels were found in 27.8%, 32.4%, 32.1% and 66.7% of patients with Dukes' A, B, C and D, respectively (p=0.001). High CA 242 levels were found in 11.1%, 16.2%, 30.8% and 50% of patients with Dukes' A, B, C and D, respectively (p=0.001). When both markers were considered together, concurrent high CEA and CA 242 levels were found in 3.4%, 0%, 23.1% and 44% of patients with Dukes' A, B, C and D, respectively (p <0.001) (Tab. I). High levels of either of the two markers were found in 33.3%, 48.6%, 40.7% and 72.5% of the patients with Dukes' A, B, C and D, respectively (p <0.006) (Tab. I). The ROC curve revealed greater areas for CEA for patients in all Dukes stages compared to CA 242, which is indicative of a greater accuracy of CEA (Fig. 1) .
The average duration of follow-up was 22.59 months. During follow-up the preoperative values for CEA and CA 242 were evaluated in relation to the specific mortality rates and survival.
The overall mortality rate in our series was 35.1% (47 of 134 patients), and the specific mortality rate 17.9% (24 of 134 patients). The specific mortality rate was 5.6% The specific mortality was 28.33% (17/60) in patients with high CEA and 9.46% (7/74) in those with normal CEA. This difference was statistically significant (p=0.005). Among the patients treated radically the specific mortality was 10% (3/30) for those with high CEA and 3.33% (2/60) for those with normal CEA, without any statistically significant difference (p=0.328). The specific mortality was 31.71% (13/41) for patients with high CA 242 and 12.22% (11/90) for those with normal CA 242. This difference was statistically significant (p=0.008). Among the radically treated patients the specific mortality was 15% (3/20) for those with high CA 242 and 2.94% (2/68) for those with normal CA 242, without any statistically significant difference (p=0.075). Comparison between CEA and CA 242 with regard to the specific mortality of radically treated patients showed no statistically significant difference (p=1).
For patients with simultaneously elevated CEA and CA 242 the specific mortality was 41.38% (12/29), while it was 11.76% (12/102) for patients in whom this association was absent. This difference was statistically significant (p <0.001). The specific mortality was 27.27% (3/11) for radically treated patients who had concurrent high CEA and CA 242, whereas it was 2.60% (2/77) for those without this association. This difference was statistically significant (p=0.013).
Analysis by means of the Kaplan-Meier curve revealed that the 60 patients with high preoperative CEA had an average survival of 44.26 months versus 61.79 months for the 74 patients with normal CEA levels. The difference observed between these two patient groups was statistically significant (p=0.0013). This survival probability is expressed by the Kaplan-Meier curve in Figure 2 . However, no statistically significant difference was observed when only patients who underwent radical surgery were considered (p=0.22).
The average survival of the 41 patients with high preoperative CA 242 levels and the 90 patients with normal levels was 38.17 months and 59.89 months, respectively. This difference was statistically significant (p=0.0002). This survival probability is expressed by the Kaplan-Meier curve in Figure 3 . The difference remained statistically significant (p=0.0061) when the 20 patients with high preoperative CA 242 levels who underwent radical Figure 4 . The 29 patients with high levels of both markers had an average survival of 29.67 months compared with 59.94 months for the 102 patients without this characteristic. This difference was statistically significant (p <0.0001). When analyzing the 11 patients with high levels of both markers who underwent radical surgery, we observed an average survival of 44.8 months versus 67.8 months for the 77 patients without this combination. This difference was also statistically significant (p=0.001). This survival probability is expressed by the Kaplan-Meier curve in Figure 5 .
DISCUSSION
Although CEA continues to be the best marker available for colorectal cancer, it cannot be considered ideal (2, 11, 12, 21, 25) . Recent research has demonstrated the importance of CA 242 through analysis of the association between its value and that of CEA in the postoperative prognosis of these patients and their monitoring during chemotherapy and radiotherapy (2, 8, 11, 14, 21, 27, 28) .
The relationship between serum CEA levels and staging shows poor sensitivity in the initial Dukes stages, es-pecially Dukes' A (11, 27, 28) . Carpelan-Holmström et al (11) reported sensitivities of 26%, 32%, 38% and 77% for Dukes' A, B, C and D, respectively, values that are similar to our results. We also found reports in the literature (11, 12, 30) of poor sensitivity in patients with Dukes' stage A and B with respect to the relationship between CA 242 assays and staging. Although Carpelan-Holmström et al (11) in their comparative study between CEA and CA 242 reported similar sensitivity for the two markers, our results for CA 242 were inferior to those for CEA for all Dukes stages, which was demonstrated by means of ROC curve analysis. These results show that neither CEA nor CA 242 can be considered adequate markers for the initial stages of the disease. However, when analyzing elevations in the levels of both markers together we observed an increase in sensitivity also in the initial stages of colorectal cancer. This is in agreement with reports by other researchers (8, 11, 12, 31) and shows the usefulness of associating the two tumor markers.
The specific mortality found in the present study (17.9%) can be considered low. This was probably the result of the limited duration of follow-up. In patients who underwent radical surgery we did not observe any significant relationship between the specific mortality for either high CEA or high CA 242 levels. However, when concurrent elevation of CEA and CA 242 levels was considered, we did identify a significant relationship, thereby demonstrating the importance of such an association 
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Survival rate with regard to the specific mortality. The high negative predictive value of these markers, both alone and in association, among radically treated patients indicates the possible importance of the use of these markers with regard to the specific mortality.
High preoperative CEA and CA 242 levels may also be related to a shorter survival (2, 21, 29) . The specific mortality values calculated from our sample served as the basis for survival analysis. The average survival of the 60 patients with high CEA levels was shorter than that of the 74 patients with normal CEA levels. However, among patients who underwent radical surgery no statistically significant difference was observed. This can probably be attributed to the inclusion of patients submitted to palliative surgery in the study sample. Because their disease is at an advanced stage, such patients more frequently have high levels of CEA (11, 27, 30) .
The average survival of the 41 patients with high CA 242 levels was shorter than that of the 90 patients with normal levels. In the patients who underwent radical surgery the difference remained statistically significant. This was not seen for CEA, suggesting that high preoperative CA 242 levels are more important than CEA levels in predicting the survival of patients submitted to radical surgery.
The average survival of the 29 patients with concurrent elevation of CEA and CA 242 was shorter than that of the 102 patients without this characteristic. When only patients who underwent radical surgery were considered, the difference remained statistically significant. These results indicate the importance of using both markers combined in survival analysis, in agreement with reports in the literature (21) .
The importance of CA 242 in prognosis was demonstrated by the shorter survival of patients with high preoperative levels of this marker, especially when associated with high preoperative levels of CEA. This observation suggests the need for stricter postoperative monitoring of such patients.
In conclusion, CA 242 appears to have less efficacy than CEA for colorectal cancer staging. The efficacy could be improved by the combined use of the two markers. CA 242 appears to be significantly more efficacious than CEA in relation to survival; the sensitivity can be improved by combining the two markers.
